Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
$25.44
$1.23M1.4122,322 shsN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$0.94
+10.4%
$1.02
$0.73
$148.00
$4.65M2.58701,457 shs431,072 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.29
-2.8%
$0.37
$0.22
$4.79
$12.28M-0.281.09 million shs290,910 shs
Q Biomed Inc. stock logo
QBIO
Q Biomed
$0.00
$0.00
$0.00
$0.03
N/A2.195,396 shs14,151 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.72
+2.7%
$0.86
$0.66
$2.29
$27.35M1.57161,346 shs53,888 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%-75.00%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
+3.16%+12.28%-18.56%-31.91%-98.80%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-0.20%+5.78%-20.13%-12.85%-84.16%
Q Biomed Inc. stock logo
QBIO
Q Biomed
0.00%0.00%0.00%-50.00%+∞
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+3.88%-5.41%-18.49%-26.21%-64.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.8203 of 5 stars
3.32.00.00.02.70.00.6
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.2974 of 5 stars
3.02.00.00.03.80.01.3
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/AN/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.7542 of 5 stars
0.03.00.00.02.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
2.50
Moderate Buy$25.002,559.86% Upside
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.00
Hold$3.381,071.88% Upside
Q Biomed Inc. stock logo
QBIO
Q Biomed
0.00
N/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ASLN, QBIO, CNSP, SCYX, and LPTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$5.37 per shareN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
$280KN/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.75M7.49N/AN/A$1.45 per share0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/A-8,454.87%-121.60%N/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$14.86M-$3,748.50N/AN/AN/A-385.41%-193.20%8/13/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)
Q Biomed Inc. stock logo
QBIO
Q Biomed
-$2.05MN/A0.00N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.56N/A14.40N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)

Latest ASLN, QBIO, CNSP, SCYX, and LPTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A-$1.58N/A-$1.58N/AN/A
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
4.94
4.94
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
2.41
2.41
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.83
5.83

Institutional Ownership

CompanyInstitutional Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
0.07%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
7.50%
Q Biomed Inc. stock logo
QBIO
Q Biomed
28.20%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionOptionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
55.46 million5.46 millionNot Optionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable
Q Biomed Inc. stock logo
QBIO
Q Biomed
3N/AN/ANot Optionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million37.12 millionOptionable

Recent News About These Companies

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 07/1/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$0.94 +0.09 (+10.43%)
Closing price 04:00 PM Eastern
Extended Trading
$0.93 -0.01 (-1.48%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.29 -0.01 (-2.80%)
Closing price 04:00 PM Eastern
Extended Trading
$0.30 +0.01 (+2.43%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Q Biomed stock logo

Q Biomed OTCMKTS:QBIO

$0.0001 0.00 (0.00%)
As of 06/30/2025 09:57 AM Eastern

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.72 +0.02 (+2.72%)
Closing price 04:00 PM Eastern
Extended Trading
$0.74 +0.02 (+2.62%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.